Smith+Nephew Lowers Revenue Forecast Despite Strong Profit Gains
SNN is trading near its 52-week low of $28.555 (6.4% above the low).
Summary
Smith+Nephew reported Q2/H1 2026 results: trading profit up 8.1% on efficiency savings, but revenue growth missed expectations, leading to a cut in full-year revenue guidance from ~6% to ~4%. Profit and cash flow guidance maintained.
Key Events · Earnings and Guidance · SNN
-
Revenue Miss, Guidance Cut
Q2 underlying revenue grew only 1.6% (vs. expectations), and full-year revenue guidance was lowered to ~4% from ~6%, driven by softness in US Orthopaedics and Advanced Wound Bioactives.
-
Profit Beat on Efficiency Gains
H1 trading profit rose 8.1% to $566M, with margin expanding 60bps to 18.3%, as $130M in efficiency savings more than offset revenue headwinds.
-
Full-Year Profit Guidance Maintained
Despite the revenue cut, management reiterated ~8% trading profit growth (ex-acquisitions), ~$800M free cash flow, and >10% adjusted ROIC, citing an additional $50M in identified savings.
-
Share Buyback and Dividend Increase
The $500M buyback program is on track with $216M settled; interim dividend raised 4% to 15.6¢ per share, signaling confidence in cash generation.
Analysis · SNN · Industrial Applications And Services
Smith+Nephew delivered a mixed bag: trading profit jumped 8.1% on efficiency gains, but revenue growth disappointed, forcing a cut to the full-year top-line guide from ~6% to ~4%. The profit beat and maintained guidance on trading profit, free cash flow, and ROIC show the 12-Point Plan is working — the company is getting leaner even as demand softens. The revenue miss, driven by US Orthopaedics and wound bioactives, raises questions about the pace of the RISE strategy. The buyback and dividend hike signal confidence, but the lowered revenue bar will test whether new product launches can reaccelerate growth in H2.
At the time of this filing, SNN was trading at $30.39 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $13.5B. The 52-week trading range was $28.56 to $38.79. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.